A Phase 3 interventional study of Cyclobenzaprine HCl and Placebo in Neck Pain, Back Pain and Spasm, sponsored by Takeda. Completed at 10 sites in Russian Federation. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-04-08.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.
The drug being tested in this study was cyclobenzaprine hydrochloride (HCl) extended-release (CER). CER was being tested to treat participants who had muscle spasms associated with acute painful musculoskeletal conditions. This study looked at medication helpfulness, relief from muscle spasms and pain, and improvement in range of motion and daily living activities.
The study enrolled 180 participants. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups which remained undisclosed to the participant and study doctor during the study:
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in the Russian Federation. The overall time to participate in this study was up to 45 days. Participants made multiple visits to the clinic, and were contacted by telephone after the last dose of study drug for a follow-up assessment.
1,363 studies on the registry are indexed under Neck Pain; 300 are open to participants now.
This study's enrollment of 180 is above the median of 50 across 1,117 interventional studies indexed under Neck Pain.
Browse Neck Pain studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Takes or took within last 14 days medications, such as:
Has a history or clinical manifestations of significant medical condition, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
Drug: Cyclobenzaprine HCl
Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
Drug: Placebo
Cyclobenzaprine HCl extended-release capsules
Also known as: Myorix®, AMRIX®
Cyclobenzaprine HCl extended release placebo-matching capsules
Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment
Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".
Time frame: Day 3
Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment
Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".
Time frame: Days 7 and 14
Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment
The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
Time frame: Day 3
Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment
The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
Time frame: Days 7 and 15
Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment
Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
Time frame: Days 3, 7, and 14
Percentage of Responders on Days 3, 7, and 14 of Treatment
A responder was defined as a participant who had both a rating of either "very good" or "excellent" for the participant's rating of medication helpfulness.
Time frame: Days 3, 7, and 14
Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment
The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
Time frame: Days 3, 7, and 15
Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment
The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
Time frame: Days 3, 7, and 15
Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment
The investigator assessed limitation of range of motion. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
Time frame: Days 3, 7, and 15
Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment
The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
Time frame: Days 3, 7, and 15
Participants took part in the study at 10 investigative sites in the Russian Federation from 12 October 2016 to 14 March 2017.
| Milestone | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Started | 90 | 90 |
| Completed | 89 | 88 |
| Not completed | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Subject decision, caused by ae influenza | 1 | 1 |
Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 0=poor | 20.0 | 28.9 |
| Day 3, 1=fair | 60.0 | 46.7 |
| Day 3, 2=good | 16.7 | 22.2 |
| Day 3, 3=very good | 3.3 | 2.2 |
| Day 3, 4=excellent | 0.0 | 0.0 |
Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 7, 0=poor | 7.8 | 16.7 |
| Day 7, 1=fair | 41.1 | 34.4 |
| Day 7, 2=good | 35.6 | 34.4 |
| Day 7, 3=very good | 13.3 | 11.1 |
| Day 7, 4=excellent | 2.2 | 3.3 |
| Day 14, 0=poor | 8.9 | 14.4 |
| Day 14, 1=fair | 25.6 | 25.6 |
| Day 14, 2=good | 25.6 | 28.9 |
| Day 14, 3=very good | 22.2 | 20.0 |
| Day 14, 4=excellent | 17.8 | 11.1 |
The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=worse | 1.1 | 0.0 |
| Day 3, 2=no change | 52.2 | 68.9 |
| Day 3, 3=slight improvement | 35.6 | 25.6 |
| Day 3, 4=moderate improvement | 11.1 | 3.3 |
| Day 3, 5=marked improvement | 0.0 | 2.2 |
The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 7, 1=worse | 2.2 | 0.0 |
| Day 7, 2=no change | 8.9 | 26.7 |
| Day 7, 3=slight improvement | 52.2 | 44.4 |
| Day 7, 4=moderate improvement | 27.8 | 24.4 |
| Day 7, 5=marked improvement | 8.9 | 4.4 |
| Day 15, 1=worse | 1.1 | 1.1 |
| Day 15, 2=no change | 5.6 | 11.1 |
| Day 15, 3=slight improvement | 27.8 | 34.4 |
| Day 15, 4=moderate improvement | 30.0 | 32.2 |
| Day 15, 5=marked improvement | 35.6 | 21.1 |
Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=worse | 3.3 | 1.1 |
| Day 3, 2=no change | 45.6 | 56.7 |
| Day 3, 3=slight improvement | 47.8 | 33.3 |
| Day 3, 4=moderate improvement | 3.3 | 7.8 |
| Day 3, 5=marked improvement | 0.0 | 1.1 |
| Day 7, 1=worse | 4.4 | 1.1 |
| Day 7, 2=no change | 13.3 | 25.6 |
| Day 7, 3=slight improvement | 52.2 | 43.3 |
| Day 7, 4=moderate improvement | 22.2 | 25.6 |
| Day 7, 5=marked improvement | 7.8 | 4.4 |
| Day 14, 1=worse | 1.1 | 1.1 |
| Day 14, 2=no change | 14.4 | 26.7 |
| Day 14, 3=slight improvement | 24.4 | 20.0 |
| Day 14, 4=moderate improvement | 27.8 | 28.9 |
| Day 14, 5=marked improvement | 32.2 | 23.3 |
A responder was defined as a participant who had both a rating of either "very good" or "excellent" for the participant's rating of medication helpfulness.
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3 | 3.3 | 2.2 |
| Day 7 | 15.6 | 14.4 |
| Day 14 | 40.0 | 31.1 |
The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=none | 2.2 | 2.2 |
| Day 3, 2=mild | 27.8 | 21.1 |
| Day 3, 3=moderate | 62.2 | 66.7 |
| Day 3, 4=moderately severe | 7.8 | 10.0 |
| Day 3, 5=severe | 0.0 | 0.0 |
| Day 7, 1=none | 14.4 | 5.6 |
| Day 7, 2=mild | 47.8 | 53.3 |
| Day 7, 3=moderate | 37.8 | 38.9 |
| Day 7, 4=moderately severe | 0.0 | 2.2 |
| Day 7, 5=severe | 0.0 | 0.0 |
| Day 15, 1=none | 48.9 | 32.2 |
| Day 15, 2=mild | 37.8 | 47.8 |
| Day 15, 3=moderate | 13.3 | 20.0 |
| Day 15, 4=moderately severe | 0.0 | 0.0 |
| Day 15, 5=severe | 0.0 | 0.0 |
The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=none | 1.1 | 1.1 |
| Day 3, 2=mild | 24.4 | 21.1 |
| Day 3, 3=moderate | 66.7 | 66.7 |
| Day 3, 4=moderately severe | 7.8 | 11.1 |
| Day 3, 5=severe | 0.0 | 0.0 |
| Day 7, 1=none | 6.7 | 2.2 |
| Day 7, 2=mild | 55.6 | 50.0 |
| Day 7, 3=moderate | 36.7 | 46.7 |
| Day 7, 4=moderately severe | 1.1 | 1.1 |
| Day 7, 5=severe | 0.0 | 0.0 |
| Day 15, 1=none | 35.6 | 25.6 |
| Day 15, 2=mild | 51.1 | 50.0 |
| Day 15, 3=moderate | 12.2 | 24.4 |
| Day 15, 4=moderately severe | 1.1 | 0.0 |
| Day 15, 5=severe | 0.0 | 0.0 |
The investigator assessed limitation of range of motion. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
| percentage of participants | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=none | 6.7 | 4.4 |
| Day 3, 2=mild | 40.0 | 37.8 |
| Day 3, 3=moderate | 47.8 | 52.2 |
| Day 3, 4=moderately severe | 5.6 | 5.6 |
| Day 3, 5=severe | 0.0 | 0.0 |
| Day 7, 1=none | 22.2 | 13.3 |
| Day 7, 2=mild | 51.1 | 51.1 |
| Day 7, 3=moderate | 26.7 | 35.6 |
| Day 7, 4=moderately severe | 0.0 | 0.0 |
| Day 7, 5=severe | 0.0 | 0.0 |
| Day 15, 1=none | 44.4 | 38.9 |
| Day 15, 2=mild | 48.9 | 47.8 |
| Day 15, 3=moderate | 6.7 | 13.3 |
| Day 15, 4=moderately severe | 0.0 | 0.0 |
| Day 15, 5=severe | 0.0 | 0.0 |
The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".
| percentage of percentage | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| Day 3, 1=none | 4.4 | 5.6 |
| Day 3, 2=mild | 46.7 | 50.0 |
| Day 3, 3=moderate | 46.7 | 38.9 |
| Day 3, 4=moderately severe | 2.2 | 5.6 |
| Day 3, 5=severe | 0.0 | 0.0 |
| Day 7, 1=none | 18.9 | 10.0 |
| Day 7, 2=mild | 62.2 | 63.3 |
| Day 7, 3=moderate | 17.8 | 26.7 |
| Day 7, 4=moderately severe | 1.1 | 0.0 |
| Day 7, 5=severe | 0.0 | 0.0 |
| Day 15, 1=none | 50.0 | 41.1 |
| Day 15, 2=mild | 45.6 | 53.3 |
| Day 15, 3=moderate | 4.4 | 5.6 |
| Day 15, 4=moderately severe | 0.0 | 0.0 |
| Day 15, 5=severe | 0.0 | 0.0 |
Collected over First dose of study drug to within 30 days of last dose of study drug (Up to 45 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclobenzaprine HCl 15 mg | 0/90 (0%) | 0/90 (0%) | 21/90 (23.3%) |
| Placebo | 0/90 (0%) | 0/90 (0%) | 12/90 (13.3%) |
| Event | Cyclobenzaprine HCl 15 mg | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 18/90 | 5/90 |
| Dry mouthGastrointestinal disorders | 6/90 | 1/90 |
| FlatulenceGastrointestinal disorders | 1/90 | 2/90 |
| Poor quality sleepNervous system disorders | 1/90 | 2/90 |
| TachycardiaCardiac disorders | 1/90 | 0/90 |
| ToothacheGastrointestinal disorders | 1/90 | 0/90 |
| InfluenzaInfections and infestations | 1/90 | 1/90 |
| RhinitisInfections and infestations | 1/90 | 0/90 |
| DizzinessNervous system disorders | 1/90 | 0/90 |
| DysgeusiaNervous system disorders | 1/90 | 0/90 |
Full Analysis Set (FAS) included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.
| Age, Continuous(years) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Mean | 33.0 ± 9.0 | 31.5 ± 9.2 | 32.3 ± 9.1 |
| Sex: Female, Male(Participants) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Female | 48 | 62 | 110 |
| Male | 42 | 28 | 70 |
| Race/Ethnicity, Customized(Participants) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| European (Caucasian) | 90 | 90 | 180 |
| Region of Enrollment(Participants) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Russia | 90 | 90 | 180 |
| Smoking Status(Participants) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Never smoked | 78 | 79 | 157 |
| Former smoker | 1 | 3 | 4 |
| Current smoker | 11 | 8 | 19 |
| Height(cm) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Mean | 171.8 ± 8.2 | 169.1 ± 7.6 | 170.5 ± 8.0 |
| Weight(kg) | Cyclobenzaprine HCl 15 mg | Placebo | Total |
|---|---|---|---|
| Mean | 71.05 ± 14.53 | 66.22 ± 13.61 | 68.64 ± 14.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Feb 2017, 3 months.
Results were first posted in Apr 2019, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine